Treating solid tumors with CAR-T therapy has been challenging due to difficulties in preserving cells health and function during the editing and bioprocessing stages.
A recent study published in Molecular Therapy: Methods & Clinical Development introduces a novel solution to these challenges: Solupore®, a non-viral transfection system for CAR-T cell manufacturing. The research demonstrates that Solupore® enhances the viability and functionality of CAR-T cells, improving their viability as a promising therapeutic option for solid tumors.
Traditional CAR-T cell manufacturing often relies on electroporation, which induces significant cellular stress, reduces cell viability, and impairs the retention of crucial T-cell subsets such as T stem cell memory (TSCM) cells. These cells are critical for long-term persistence and efficacy, especially in the hostile microenvironment of solid tumors.
Solupore® addresses key hurdles in solid tumor therapy by preserving CAR-T cell health and potency during production. Its ability to support complex genetic modifications paves the way for next-generation CAR-T cells capable of overcoming tumor-mediated immunosuppression. With its scalable and GMP-compliant design, the Solupore® platform marks a significant step forward in CAR-T therapy for solid tumors.
Read the whole publication following the link below.